<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Carnitine Palmitoyltransferase II Deficiency - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-name-link {
            color: inherit;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
        }

        .item-name-link:hover {
            text-decoration-thickness: 2px;
        }

        .missing-disease-name {
            color: #991b1b;
            border-bottom: 1px dotted #dc2626;
        }

        .curation-gap-badge {
            display: inline-flex;
            align-items: center;
            margin-left: 8px;
            padding: 2px 8px;
            border-radius: 999px;
            font-size: 0.72rem;
            font-weight: 700;
            letter-spacing: 0.01em;
            text-transform: uppercase;
            background: #fef2f2;
            border: 1px solid #fecaca;
            color: #b91c1c;
            vertical-align: middle;
        }

        .missing-ontology-link {
            color: #b91c1c !important;
            text-decoration: underline dotted;
            text-underline-offset: 2px;
        }

        .dismech-inline-link {
            margin-left: 6px;
            font-size: 0.78rem;
            font-weight: 600;
            color: #0369a1;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
            white-space: nowrap;
        }

        .dismech-inline-link:hover {
            text-decoration-thickness: 2px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Carnitine Palmitoyltransferase II Deficiency</span>
        </nav>

        <header class="page-header">
            <h1>Carnitine Palmitoyltransferase II Deficiency</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Mendelian</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0015515" target="_blank">
                        MONDO:0015515
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Fatty Acid Oxidation Disorder</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Inborn Error of Metabolism</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Carnitine palmitoyltransferase II (CPT-II) deficiency is an autosomal recessive inborn error of mitochondrial long-chain fatty acid oxidation caused by biallelic pathogenic variants in CPT2. CPT-II is an inner mitochondrial membrane enzyme that reconverts long-chain acylcarnitines back to long-chain acyl-CoA for entry into beta-oxidation, forming the final step of the carnitine shuttle. Three clinical phenotypes are recognized: a lethal neonatal form, a severe infantile hepatocardiomuscular form, and the most common adult myopathic form characterized by recurrent exercise- or illness-triggered myalgia, rhabdomyolysis, and myoglobinuria. A literature review identified 245 documented CPT2 cases distributed as 21 lethal neonatal, 32 severe infantile hepatocardiomuscular, and 192 myopathic.

            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">10</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <a class="stat-link" href="#trials">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Trials</div>
            </div>
            </a>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">hereditary disease</span>
                    
                </div>
            </div>
            
            
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Impaired mitochondrial long-chain fatty acid oxidation</div>
                
                <div class="item-desc">Loss of CPT-II function impairs mitochondrial beta-oxidation of long-chain fatty acids, resulting in accumulation of long-chain acylcarnitines and disruption of energy homeostasis, especially during fasting, illness, fever, or prolonged exercise when reliance on fatty acid oxidation increases.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        skeletal muscle fiber
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0008002" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        hepatocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000182" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        fatty acid beta-oxidation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006635" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        long-chain fatty acid metabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0001676" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        mitochondrion
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005739" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28054946" target="_blank">PMID:28054946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"CPT (carnitine palmitoyltransferase) II muscle deficiency is the most common form of muscle fatty acid metabolism disorders."</div>
                
                
                <div class="evidence-explanation">Directly supports impaired fatty acid oxidation as the core defect in CPT II deficiency.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Thermolability of mutant CPT-II enzyme</div>
                
                <div class="item-desc">The common myopathic variant p.Ser113Leu produces an enzyme with near-normal baseline activity but marked thermolability at elevated temperatures (40-45 degrees C) and abnormal sensitivity to inhibition by malonyl-CoA. This provides a mechanistic rationale for fever- and exertion-triggered metabolic crises, as the mutant enzyme loses activity precisely when fatty acid oxidation demand is greatest.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        protein folding
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006457" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28054946" target="_blank">PMID:28054946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"the wild-type and the S113L variants showed the same enzymatic activity. However, the mutated enzyme showed an abnormal thermal destabilization at 40 and 45 ¬∞C and an abnormal sensitivity to inhibition by malony-CoA."</div>
                
                
                <div class="evidence-explanation">Demonstrates thermolability of S113L variant and abnormal malonyl-CoA sensitivity using recombinant enzymes.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28054946" target="_blank">PMID:28054946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"The thermolability of the mutant enzyme might explain why symptoms in muscle CPT II deficiency mainly occur during prolonged exercise, infections and exposure to cold."</div>
                
                
                <div class="evidence-explanation">Links thermolability mechanism to clinical trigger factors.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">LCAC-mediated calcium dyshomeostasis in skeletal muscle</div>
                
                <div class="item-desc">In CPT2-deficient muscle, accumulation of long-chain acylcarnitines (LCACs), particularly palmitoyl-carnitine, directly inhibits sarcoplasmic reticulum calcium uptake, disrupts excitation-contraction coupling structures, and increases mitochondrial calcium stress and permeability transition pore susceptibility. This leads to contractile dysfunction and myofiber injury beyond simple energy failure.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        skeletal muscle fiber
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0008002" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        calcium ion homeostasis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0055074" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        sarcoplasmic reticulum
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0016529" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39182841" target="_blank">PMID:39182841</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"Exposing isolated sarcoplasmic reticulum to long-chain acylcarnitines (LCACs) inhibited calcium uptake."</div>
                
                
                <div class="evidence-explanation">Directly demonstrates LCAC-mediated inhibition of SR calcium uptake in CPT2-deficient muscle model.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Carnitine shuttle disruption</div>
                
                <div class="item-desc">CPT-II is the final enzyme of the three-component carnitine shuttle that transports long-chain fatty acids into the mitochondrial matrix. CPT-I on the outer mitochondrial membrane converts acyl-CoA to acylcarnitine, CACT translocates acylcarnitine across the inner membrane, and CPT-II regenerates acyl-CoA inside the mitochondrion. Loss of CPT-II activity blocks this shuttle at its terminal step.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        carnitine shuttle
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006853" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        mitochondrial inner membrane
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005743" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28054946" target="_blank">PMID:28054946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The carnitine palmitoyltransferase (CPT) system consists of two enzymes, CPT I and CPT II, and is involved in the transport of long-chain fatty acids into the mitochondrial compartment. The enzymes are located in the outer (CPT I) and inner mitochondrial membrane (CPT II)."</div>
                
                
                <div class="evidence-explanation">Describes the carnitine shuttle system and localization of CPT-I and CPT-II.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Carnitine_shuttle_disruption[&#34;Carnitine shuttle disruption&#34;]
    LCAC_mediated_calcium_dyshomeostasis_in_skeletal_muscle[&#34;LCAC-mediated calcium dyshomeostasis in skeletal muscle&#34;]
    Impaired_mitochondrial_long_chain_fatty_acid_oxidation[&#34;Impaired mitochondrial long-chain fatty acid oxidation&#34;]
    Thermolability_of_mutant_CPT_II_enzyme[&#34;Thermolability of mutant CPT-II enzyme&#34;]

    Impaired_mitochondrial_long_chain_fatty_acid_oxidation --&gt; LCAC_mediated_calcium_dyshomeostasis_in_skeletal_muscle
    Thermolability_of_mutant_CPT_II_enzyme --&gt; Impaired_mitochondrial_long_chain_fatty_acid_oxidation
    Carnitine_shuttle_disruption --&gt; Impaired_mitochondrial_long_chain_fatty_acid_oxidation

    style Carnitine_shuttle_disruption fill:#dbeafe
    style LCAC_mediated_calcium_dyshomeostasis_in_skeletal_muscle fill:#dbeafe
    style Impaired_mitochondrial_long_chain_fatty_acid_oxidation fill:#dbeafe
    style Thermolability_of_mutant_CPT_II_enzyme fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">10</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Cardiovascular<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Digestive<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Genitourinary<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Metabolism<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-5">Musculoskeletal<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-6">Constitutional<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-7">Other<span class="pill-count">(3)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Cardiovascular
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Cardiomyopathy
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001638" target="_blank">
                                Cardiomyopathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001638)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37933340" target="_blank">PMID:37933340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Echocardiogram showed a left ventricle ejection fraction (LVEF) of 40%."</div>
                
                
                <div class="evidence-explanation">Documents cardiomyopathy with reduced ejection fraction in a myopathic CPT II patient.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37933340" target="_blank">PMID:37933340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The first two are early-onset severe disorders presenting with marked hypoketotic hypoglycemia, cardiomyopathy, and liver dysfunction."</div>
                
                
                <div class="evidence-explanation">Identifies cardiomyopathy as a feature of severe early-onset CPT II deficiency.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Digestive
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hepatomegaly
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002240" target="_blank">
                                Hepatomegaly
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002240)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37933340" target="_blank">PMID:37933340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The first two are early-onset severe disorders presenting with marked hypoketotic hypoglycemia, cardiomyopathy, and liver dysfunction."</div>
                
                
                <div class="evidence-explanation">Liver dysfunction in early-onset forms is consistent with hepatomegaly.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Genitourinary
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Acute kidney injury
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001919" target="_blank">
                                Acute kidney injury
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001919)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28054946" target="_blank">PMID:28054946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical features are attacks of muscle weakness, myalgia, pain and rhabdomyolysis with or without renal failure."</div>
                
                
                <div class="evidence-explanation">Lists renal failure as a complication of rhabdomyolysis in CPT II deficiency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37933340" target="_blank">PMID:37933340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"One of the most common complications is acute kidney injury (AKI) following massive rhabdomyolysis, which is managed with aggressive fluid therapy"</div>
                
                
                <div class="evidence-explanation">Directly identifies AKI as a common rhabdomyolysis complication in CPT II deficiency.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Metabolism
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hypoketotic hypoglycemia
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001985" target="_blank">
                                Hypoketotic hypoglycemia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001985)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37933340" target="_blank">PMID:37933340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The first two are early-onset severe disorders presenting with marked hypoketotic hypoglycemia, cardiomyopathy, and liver dysfunction."</div>
                
                
                <div class="evidence-explanation">Confirms hypoketotic hypoglycemia as a hallmark of severe early-onset CPT II forms.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Elevated creatine kinase
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003236" target="_blank">
                                Elevated circulating creatine kinase concentration
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003236)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38650450" target="_blank">PMID:38650450</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"3 cases presented with clinical manifestations of fever, muscle weakness, and increased muscle enzymes."</div>
                
                
                <div class="evidence-explanation">Documents increased muscle enzymes (including CK) as a clinical manifestation in CPT2-deficient children.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-5">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Musculoskeletal
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Muscle weakness
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001324" target="_blank">
                                Muscle weakness
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001324)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28054946" target="_blank">PMID:28054946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Following the main clinical symptoms were myoglobinuria (86%) and muscle weakness (76%)"</div>
                
                
                <div class="evidence-explanation">Quantifies muscle weakness at 76% in myopathic CPT II cohort.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-6">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Constitutional
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Myalgia
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003326" target="_blank">
                                Myalgia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003326)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28054946" target="_blank">PMID:28054946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Almost all patients (94%) described attacks of myalgia."</div>
                
                
                <div class="evidence-explanation">Quantifies myalgia at 94% in cohort study of 50 patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37933340" target="_blank">PMID:37933340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"We report an otherwise healthy 38-year-old patient who presented with severe myalgia, cramps, fatigue, low-grade fever, and transient myoglobinuria, after intense physical training."</div>
                
                
                <div class="evidence-explanation">Case report illustrating typical exercise-triggered myalgia presentation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-7">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">3</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Rhabdomyolysis
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003201" target="_blank">
                                Rhabdomyolysis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003201)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28054946" target="_blank">PMID:28054946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical features are attacks of muscle weakness, myalgia, pain and rhabdomyolysis with or without renal failure."</div>
                
                
                <div class="evidence-explanation">Directly lists rhabdomyolysis as a clinical feature of muscle CPT II deficiency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28054946" target="_blank">PMID:28054946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Following the main clinical symptoms were myoglobinuria (86%) and muscle weakness (76%)"</div>
                
                
                <div class="evidence-explanation">Quantifies myoglobinuria at 86% in a cohort of 50 patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Myoglobinuria
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002913" target="_blank">
                                Myoglobinuria
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002913)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28054946" target="_blank">PMID:28054946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Following the main clinical symptoms were myoglobinuria (86%) and muscle weakness (76%)"</div>
                
                
                <div class="evidence-explanation">Quantifies myoglobinuria at 86% in myopathic CPT II deficiency cohort.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37933340" target="_blank">PMID:37933340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"We report an otherwise healthy 38-year-old patient who presented with severe myalgia, cramps, fatigue, low-grade fever, and transient myoglobinuria, after intense physical training."</div>
                
                
                <div class="evidence-explanation">Case presentation showing transient myoglobinuria as a presenting feature.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Episodic muscle stiffness
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0008967" target="_blank">
                                Exercise-induced muscle stiffness
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0008967)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37933340" target="_blank">PMID:37933340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The latter is characterized by muscle pain and weakness and stiffness, typically triggered by exercise or febrile illnesses"</div>
                
                
                <div class="evidence-explanation">Directly describes muscle stiffness as a characteristic feature of myopathic CPT II deficiency.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    CPT2 gene variants
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal recessive</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28054946" target="_blank">PMID:28054946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Three phenotypes of CPT II deficiency are known: a lethal neonatal form, a severe infantile hepatocardiomuscular form, and a mild myopathic form"</div>
                
                
                <div class="evidence-explanation">Describes the three clinical phenotypes of CPT II deficiency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39429887" target="_blank">PMID:39429887</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The review detailed 245 cases across various forms, including lethal neonatal, severe infantile hepatocardiomuscular, and myopathic forms."</div>
                
                
                <div class="evidence-explanation">Quantifies case distribution across the three clinical subtypes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">8</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Avoidance of metabolic triggers
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Lifestyle modification to avoid prolonged exercise, fasting, cold exposure, and other metabolic stressors is the primary preventive strategy. Patients should modify daily activities to prevent recurrent rhabdomyolysis episodes.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37933340" target="_blank">PMID:37933340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The patient was discharged upon the improvement of renal function with lifestyle modification recommendations."</div>
                
                
                <div class="evidence-explanation">Supports lifestyle modification as a key management strategy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28054946" target="_blank">PMID:28054946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Trigger factors are prolonged exercise, fasting, fever and exposure to cold"</div>
                
                
                <div class="evidence-explanation">Identification of trigger factors directly supports avoidance strategy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    High-carbohydrate, low-fat diet
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000088" target="_blank">
                            MAXO:0000088
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Dietary modification emphasizing high carbohydrate and low long-chain fat intake to reduce reliance on fatty acid oxidation. Medium-chain triglyceride (MCT) supplementation may be used as an alternative energy source since MCT can bypass the carnitine shuttle.
</div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Aggressive fluid resuscitation for rhabdomyolysis
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Emergency management of acute rhabdomyolysis episodes with aggressive intravenous fluid therapy using crystalloid solutions to prevent or treat myoglobin-induced acute kidney injury.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37933340" target="_blank">PMID:37933340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"One of the most common complications is acute kidney injury (AKI) following massive rhabdomyolysis, which is managed with aggressive fluid therapy; crystalloid solutions are preferred."</div>
                
                
                <div class="evidence-explanation">Directly recommends aggressive fluid resuscitation with crystalloids for rhabdomyolysis-associated AKI.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37933340" target="_blank">PMID:37933340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Fluid resuscitation was started. Acute kidney injury was diagnosed and managed with plasmapheresis and five sessions of hemodialysis."</div>
                
                
                <div class="evidence-explanation">Documents clinical management of AKI with fluid resuscitation and renal replacement therapy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Carnitine supplementation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">L-carnitine supplementation may be used to support conjugation and excretion of accumulated long-chain acyl groups, though its use remains debated in fatty acid oxidation disorders. Free carnitine is often decreased in CPT2 deficiency.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38650450" target="_blank">PMID:38650450</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Five children presented with decreased free carnitine and elevated levels of palmitoyl and octadecenoyl carnitines."</div>
                
                
                <div class="evidence-explanation">Decreased free carnitine provides rationale for supplementation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Bezafibrate
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">A fibrate drug investigated as a potential pharmacotherapy for CPT II deficiency. A Phase 2 randomized crossover trial (NCT00983788) evaluated bezafibrate in adults with CPT II or VLCAD deficiency.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT00983788" target="_blank">clinicaltrials:NCT00983788</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The investigators propose to evaluate the effect of bezafibrate on metabolism during exercise in 22 adult patients affected with carnitine palmitoyltransferase II (CPTII) or very-long chain acyl-CoA-dehydrogenase (VLCAD) deficiencies."</div>
                
                
                <div class="evidence-explanation">Directly supports bezafibrate as a studied intervention in adults with CPT II deficiency.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Triheptanoin (UX007)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">An odd-chain triglyceride intended to provide anaplerotic substrate (propionyl-CoA) to support energy metabolism in long-chain fatty acid oxidation disorders. Phase 2 clinical trials (NCT01886378, NCT01379625) have evaluated triheptanoin in LC-FAOD patients including those with CPT II deficiency.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT01379625" target="_blank">clinicaltrials:NCT01379625</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This study will determine if a new experimental oil called Triheptanoin can decrease the muscle pain and increase the heart function and the amount of energy in patients with long-chain fatty acid oxidation disorders."</div>
                
                
                <div class="evidence-explanation">Supports triheptanoin as a clinical trial intervention for LC-FAOD populations that include CPT II deficiency.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Newborn screening
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000124" target="_blank">
                            MAXO:0000124
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">CPT II deficiency is detectable by newborn screening via tandem mass spectrometry using elevated long-chain acylcarnitines (C16, C18:1) as primary markers. Three of six children in one cohort were diagnosed through neonatal screening. However, biochemical abnormalities may only be detectable during metabolic stress.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38650450" target="_blank">PMID:38650450</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Three cases were diagnosed at neonatal screening"</div>
                
                
                <div class="evidence-explanation">Documents successful neonatal screening diagnosis in CPT2 deficiency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38650450" target="_blank">PMID:38650450</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"An early diagnosis can be facilitated by neonatal blood tandem mass spectrometry screening and genetic testing, and most patients have good prognosis after a timely diagnosis and treatment."</div>
                
                
                <div class="evidence-explanation">Supports the value of newborn screening for early diagnosis and improved outcomes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Genetic counseling
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000079" target="_blank">
                            MAXO:0000079
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Counseling for affected families regarding autosomal recessive inheritance, carrier testing, recurrence risk, and reproductive options including prenatal genetic testing.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28054946" target="_blank">PMID:28054946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The disease follows an autosomal recessive mode of inheritance."</div>
                
                
                <div class="evidence-explanation">Autosomal recessive inheritance directly supports the role of genetic counseling for carrier and recurrence risk assessment.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">üåç</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Prolonged exercise</div>
                
                
                <div class="item-desc">Exercise is the most common trigger for rhabdomyolysis episodes, reported in 87% of patients. Sustained muscle activity increases reliance on fatty acid oxidation, unmasking the enzymatic defect.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28054946" target="_blank">PMID:28054946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The most common trigger factors were exercise (87%) and infection (62%)."</div>
                
                
                <div class="evidence-explanation">Quantifies exercise as the most common trigger at 87%.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Fasting</div>
                
                
                <div class="item-desc">Fasting increases dependency on fatty acid oxidation for energy, precipitating metabolic crises.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28054946" target="_blank">PMID:28054946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Trigger factors are prolonged exercise, fasting, fever and exposure to cold"</div>
                
                
                <div class="evidence-explanation">Lists fasting as a recognized trigger factor.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Fever and infection</div>
                
                
                <div class="item-desc">Fever both increases energy demand and, in thermolabile variants, directly destabilizes the mutant CPT-II enzyme. Infections triggered episodes in 62% of patients.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28054946" target="_blank">PMID:28054946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The most common trigger factors were exercise (87%) and infection (62%)."</div>
                
                
                <div class="evidence-explanation">Infection is the second most common trigger at 62%.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28054946" target="_blank">PMID:28054946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"the mutated enzyme showed an abnormal thermal destabilization at 40 and 45 ¬∞C"</div>
                
                
                <div class="evidence-explanation">Thermolability of S113L variant at fever-range temperatures explains fever as a trigger.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Cold exposure</div>
                
                
                <div class="item-desc">Exposure to cold is a recognized trigger for metabolic crises in CPT II deficiency.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28054946" target="_blank">PMID:28054946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Trigger factors are prolonged exercise, fasting, fever and exposure to cold"</div>
                
                
                <div class="evidence-explanation">Lists cold exposure among recognized trigger factors.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Long-chain acylcarnitines (C16, C18:1)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Elevation of long-chain acylcarnitines, particularly palmitoylcarnitine (C16:0) and oleoylcarnitine (C18:1), is the hallmark biochemical signature detectable by tandem mass spectrometry. However, profiles may be normal between crises, and sampling during metabolic stress is critical.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38650450" target="_blank">PMID:38650450</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Five children presented with decreased free carnitine and elevated levels of palmitoyl and octadecenoyl carnitines."</div>
                
                
                <div class="evidence-explanation">Documents elevated C16 and C18:1 acylcarnitines in CPT2-deficient children.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Free carnitine (C0)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(DECREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Free carnitine levels may be decreased or low-normal, reflecting sequestration as long-chain acylcarnitines that cannot be metabolized due to CPT-II dysfunction.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38650450" target="_blank">PMID:38650450</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Five children presented with decreased free carnitine and elevated levels of palmitoyl and octadecenoyl carnitines."</div>
                
                
                <div class="evidence-explanation">Documents decreased free carnitine in CPT2-deficient children alongside elevated acylcarnitines.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Creatine kinase
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Markedly elevated during rhabdomyolysis episodes, reflecting skeletal muscle damage. Returns to normal between episodes. Serves as an acute marker of metabolic crisis severity.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38650450" target="_blank">PMID:38650450</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"3 cases presented with clinical manifestations of fever, muscle weakness, and increased muscle enzymes."</div>
                
                
                <div class="evidence-explanation">Increased muscle enzymes (CK) documented during symptomatic episodes in CPT2 deficiency.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Palmitoyl-carnitine in muscle
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Palmitoyl-carnitine (C16:0) accumulates preferentially in oxidative muscle fibers in CPT2 deficiency and directly inhibits sarcoplasmic reticulum calcium uptake, linking it to the pathogenesis of muscle contractile dysfunction.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39182841" target="_blank">PMID:39182841</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"Exposing isolated sarcoplasmic reticulum to long-chain acylcarnitines (LCACs) inhibited calcium uptake."</div>
                
                
                <div class="evidence-explanation">Directly supports palmitoyl-carnitine-mediated inhibition of calcium handling in muscle.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        
        <div class="card" id="trials">
            <div class="card-header">
                <div class="card-icon" style="background: #f5f3ff; color: #a855f7;">üî¨</div>
                <h2 class="card-title">Clinical Trials</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box clinical-trial-box">
                <div class="item-name">
                    NCT00983788
                    
                    <span class="tag tag-phase">PHASE_II</span>
                    
                    
                    <span class="tag tag-status">COMPLETED</span>
                    
                </div>
                
                <div class="item-desc">Randomized, double-blind, placebo-controlled crossover trial evaluating bezafibrate effects on exercise metabolism in adults with CPT II or VLCAD deficiency.</div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #6b21a8;">Target Phenotypes:</strong>
                    
                    <span class="tag" style="background: #ede9fe; color: #6b21a8; font-size: 0.8rem;">
                        Exercise intolerance
                        
                        <a href="http://purl.obolibrary.org/obo/HP_0003546" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                    <span class="tag" style="background: #ede9fe; color: #6b21a8; font-size: 0.8rem;">
                        Myopathy
                        
                        <a href="http://purl.obolibrary.org/obo/HP_0003198" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT00983788" target="_blank">clinicaltrials:NCT00983788</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This study will be an 9-month, randomized, double-blind, placebo-controlled crossover trial."</div>
                
                
                <div class="evidence-explanation">Supports trial design and intervention context for bezafibrate in CPT II/LC-FAOD disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box clinical-trial-box">
                <div class="item-name">
                    NCT01886378
                    
                    <span class="tag tag-phase">PHASE_II</span>
                    
                    
                    <span class="tag tag-status">COMPLETED</span>
                    
                </div>
                
                <div class="item-desc">Open-label Phase 2 trial evaluating UX007 (triheptanoin) clinical effects and safety in LC-FAOD.</div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #6b21a8;">Target Phenotypes:</strong>
                    
                    <span class="tag" style="background: #ede9fe; color: #6b21a8; font-size: 0.8rem;">
                        Myopathy
                        
                        <a href="http://purl.obolibrary.org/obo/HP_0003198" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                    <span class="tag" style="background: #ede9fe; color: #6b21a8; font-size: 0.8rem;">
                        Cardiomyopathy
                        
                        <a href="http://purl.obolibrary.org/obo/HP_0001638" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT01886378" target="_blank">clinicaltrials:NCT01886378</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The primary objective of the study was to evaluate the impact of UX007 on acute clinical pathophysiology associated with LC-FAOD following 24 weeks of treatment."</div>
                
                
                <div class="evidence-explanation">Supports UX007/triheptanoin as an evaluated trial intervention in LC-FAOD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box clinical-trial-box">
                <div class="item-name">
                    NCT01379625
                    
                    <span class="tag tag-phase">PHASE_II</span>
                    
                    
                    <span class="tag tag-status">COMPLETED</span>
                    
                </div>
                
                <div class="item-desc">Phase 2 trial of triheptanoin for long-chain fatty acid oxidation disorders, including outcomes relevant to muscle and cardiac function.</div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #6b21a8;">Target Phenotypes:</strong>
                    
                    <span class="tag" style="background: #ede9fe; color: #6b21a8; font-size: 0.8rem;">
                        Exercise intolerance
                        
                        <a href="http://purl.obolibrary.org/obo/HP_0003546" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                    <span class="tag" style="background: #ede9fe; color: #6b21a8; font-size: 0.8rem;">
                        Cardiomyopathy
                        
                        <a href="http://purl.obolibrary.org/obo/HP_0001638" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT01379625" target="_blank">clinicaltrials:NCT01379625</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This study will determine if a new experimental oil called Triheptanoin can decrease the muscle pain and increase the heart function and the amount of energy in patients with long-chain fatty acid oxidation disorders."</div>
                
                
                <div class="evidence-explanation">Supports triheptanoin trial targeting clinically relevant muscle and cardiac outcomes in LC-FAOD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Carnitine Palmitoyltransferase II Deficiency
category: Mendelian
creation_date: &#39;2025-06-12T20:16:27Z&#39;
updated_date: &#39;2026-02-27T00:10:00Z&#39;
classifications:
  harrisons_chapter:
  - classification_value: hereditary disease
synonyms:
- CPT II deficiency
- CPT2 deficiency
- Carnitine palmitoyl transferase 2 deficiency
- CPT-II deficiency
description: &#39;Carnitine palmitoyltransferase II (CPT-II) deficiency is an autosomal recessive inborn error of mitochondrial
  long-chain fatty acid oxidation caused by biallelic pathogenic variants in CPT2. CPT-II is an inner mitochondrial membrane
  enzyme that reconverts long-chain acylcarnitines back to long-chain acyl-CoA for entry into beta-oxidation, forming the
  final step of the carnitine shuttle. Three clinical phenotypes are recognized: a lethal neonatal form, a severe infantile
  hepatocardiomuscular form, and the most common adult myopathic form characterized by recurrent exercise- or illness-triggered
  myalgia, rhabdomyolysis, and myoglobinuria. A literature review identified 245 documented CPT2 cases distributed as 21 lethal
  neonatal, 32 severe infantile hepatocardiomuscular, and 192 myopathic.

  &#39;
disease_term:
  preferred_term: carnitine palmitoyltransferase II deficiency
  term:
    id: MONDO:0015515
    label: carnitine palmitoyltransferase II deficiency
parents:
- Fatty Acid Oxidation Disorder
- Inborn Error of Metabolism
prevalence:
- notes: Rare; one narrative review cites approximately 1-9 per 100,000. A 2024 literature review identified 245 published
    cases (21 neonatal lethal, 32 severe infantile, 192 myopathic). The myopathic form is the most common inherited disorder
    of muscle fatty acid metabolism.
progression:
- notes: In the myopathic form, metabolic crises are episodic and triggered by prolonged exercise, fasting, fever, or cold
    exposure. Between crises patients are typically asymptomatic. Severe neonatal and infantile forms follow a progressive
    multiorgan decline. Repeated rhabdomyolysis episodes can lead to cumulative renal damage.
pathophysiology:
- name: Impaired mitochondrial long-chain fatty acid oxidation
  description: &#39;Loss of CPT-II function impairs mitochondrial beta-oxidation of long-chain fatty acids, resulting in accumulation
    of long-chain acylcarnitines and disruption of energy homeostasis, especially during fasting, illness, fever, or prolonged
    exercise when reliance on fatty acid oxidation increases.

    &#39;
  biological_processes:
  - preferred_term: fatty acid beta-oxidation
    term:
      id: GO:0006635
      label: fatty acid beta-oxidation
  - preferred_term: long-chain fatty acid metabolic process
    term:
      id: GO:0001676
      label: long-chain fatty acid metabolic process
  cell_types:
  - preferred_term: skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  evidence:
  - reference: PMID:28054946
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: CPT (carnitine palmitoyltransferase) II muscle deficiency is the most common form of muscle fatty acid metabolism
      disorders.
    explanation: Directly supports impaired fatty acid oxidation as the core defect in CPT II deficiency.
  downstream:
  - target: LCAC-mediated calcium dyshomeostasis in skeletal muscle
- name: Thermolability of mutant CPT-II enzyme
  description: &#39;The common myopathic variant p.Ser113Leu produces an enzyme with near-normal baseline activity but marked
    thermolability at elevated temperatures (40-45 degrees C) and abnormal sensitivity to inhibition by malonyl-CoA. This
    provides a mechanistic rationale for fever- and exertion-triggered metabolic crises, as the mutant enzyme loses activity
    precisely when fatty acid oxidation demand is greatest.

    &#39;
  biological_processes:
  - preferred_term: protein folding
    term:
      id: GO:0006457
      label: protein folding
  evidence:
  - reference: PMID:28054946
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: the wild-type and the S113L variants showed the same enzymatic activity. However, the mutated enzyme showed an
      abnormal thermal destabilization at 40 and 45 ¬∞C and an abnormal sensitivity to inhibition by malony-CoA.
    explanation: Demonstrates thermolability of S113L variant and abnormal malonyl-CoA sensitivity using recombinant enzymes.
  - reference: PMID:28054946
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The thermolability of the mutant enzyme might explain why symptoms in muscle CPT II deficiency mainly occur during
      prolonged exercise, infections and exposure to cold.
    explanation: Links thermolability mechanism to clinical trigger factors.
  downstream:
  - target: Impaired mitochondrial long-chain fatty acid oxidation
- name: LCAC-mediated calcium dyshomeostasis in skeletal muscle
  description: &#39;In CPT2-deficient muscle, accumulation of long-chain acylcarnitines (LCACs), particularly palmitoyl-carnitine,
    directly inhibits sarcoplasmic reticulum calcium uptake, disrupts excitation-contraction coupling structures, and increases
    mitochondrial calcium stress and permeability transition pore susceptibility. This leads to contractile dysfunction and
    myofiber injury beyond simple energy failure.

    &#39;
  biological_processes:
  - preferred_term: calcium ion homeostasis
    term:
      id: GO:0055074
      label: calcium ion homeostasis
  cell_types:
  - preferred_term: skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  locations:
  - preferred_term: sarcoplasmic reticulum
    term:
      id: GO:0016529
      label: sarcoplasmic reticulum
  evidence:
  - reference: PMID:39182841
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Exposing isolated sarcoplasmic reticulum to long-chain acylcarnitines (LCACs) inhibited calcium uptake.
    explanation: Directly demonstrates LCAC-mediated inhibition of SR calcium uptake in CPT2-deficient muscle model.
- name: Carnitine shuttle disruption
  description: &#39;CPT-II is the final enzyme of the three-component carnitine shuttle that transports long-chain fatty acids
    into the mitochondrial matrix. CPT-I on the outer mitochondrial membrane converts acyl-CoA to acylcarnitine, CACT translocates
    acylcarnitine across the inner membrane, and CPT-II regenerates acyl-CoA inside the mitochondrion. Loss of CPT-II activity
    blocks this shuttle at its terminal step.

    &#39;
  biological_processes:
  - preferred_term: carnitine shuttle
    term:
      id: GO:0006853
      label: carnitine shuttle
  locations:
  - preferred_term: mitochondrial inner membrane
    term:
      id: GO:0005743
      label: mitochondrial inner membrane
  evidence:
  - reference: PMID:28054946
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The carnitine palmitoyltransferase (CPT) system consists of two enzymes, CPT I and CPT II, and is involved in
      the transport of long-chain fatty acids into the mitochondrial compartment. The enzymes are located in the outer (CPT
      I) and inner mitochondrial membrane (CPT II).
    explanation: Describes the carnitine shuttle system and localization of CPT-I and CPT-II.
  downstream:
  - target: Impaired mitochondrial long-chain fatty acid oxidation
phenotypes:
- name: Rhabdomyolysis
  frequency: VERY_FREQUENT
  description: &#39;Recurrent episodes of skeletal muscle breakdown triggered by prolonged exercise, fasting, fever, or cold exposure.
    This is the hallmark manifestation of the myopathic form. In a cohort of 50 patients, myoglobinuria was observed in 86%.

    &#39;
  phenotype_term:
    preferred_term: Rhabdomyolysis
    term:
      id: HP:0003201
      label: Rhabdomyolysis
  evidence:
  - reference: PMID:28054946
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Clinical features are attacks of muscle weakness, myalgia, pain and rhabdomyolysis with or without renal failure.
    explanation: Directly lists rhabdomyolysis as a clinical feature of muscle CPT II deficiency.
  - reference: PMID:28054946
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Following the main clinical symptoms were myoglobinuria (86%) and muscle weakness (76%)
    explanation: Quantifies myoglobinuria at 86% in a cohort of 50 patients.
- name: Myalgia
  frequency: VERY_FREQUENT
  description: &#39;Recurrent attacks of muscle pain are the most common symptom, reported in 94% of patients with muscle CPT
    II deficiency. Typically triggered by exercise, infection, or fasting.

    &#39;
  phenotype_term:
    preferred_term: Myalgia
    term:
      id: HP:0003326
      label: Myalgia
  evidence:
  - reference: PMID:28054946
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Almost all patients (94%) described attacks of myalgia.
    explanation: Quantifies myalgia at 94% in cohort study of 50 patients.
  - reference: PMID:37933340
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We report an otherwise healthy 38-year-old patient who presented with severe myalgia, cramps, fatigue, low-grade
      fever, and transient myoglobinuria, after intense physical training.
    explanation: Case report illustrating typical exercise-triggered myalgia presentation.
- name: Muscle weakness
  frequency: FREQUENT
  description: &#39;Episodic muscle weakness during attacks, reported in 76% of patients. Unlike carnitine deficiency, persistent
    muscle weakness is not characteristic between episodes.

    &#39;
  phenotype_term:
    preferred_term: Muscle weakness
    term:
      id: HP:0001324
      label: Muscle weakness
  evidence:
  - reference: PMID:28054946
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Following the main clinical symptoms were myoglobinuria (86%) and muscle weakness (76%)
    explanation: Quantifies muscle weakness at 76% in myopathic CPT II cohort.
- name: Myoglobinuria
  frequency: VERY_FREQUENT
  description: &#39;Dark urine due to myoglobin release from damaged skeletal muscle, occurring with rhabdomyolysis episodes.
    Reported in 86% of patients with the myopathic form.

    &#39;
  phenotype_term:
    preferred_term: Myoglobinuria
    term:
      id: HP:0002913
      label: Myoglobinuria
  evidence:
  - reference: PMID:28054946
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Following the main clinical symptoms were myoglobinuria (86%) and muscle weakness (76%)
    explanation: Quantifies myoglobinuria at 86% in myopathic CPT II deficiency cohort.
  - reference: PMID:37933340
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We report an otherwise healthy 38-year-old patient who presented with severe myalgia, cramps, fatigue, low-grade
      fever, and transient myoglobinuria, after intense physical training.
    explanation: Case presentation showing transient myoglobinuria as a presenting feature.
- name: Acute kidney injury
  frequency: OCCASIONAL
  description: &#39;Renal failure secondary to massive rhabdomyolysis and myoglobin nephrotoxicity. Managed with aggressive fluid
    resuscitation and occasionally hemodialysis.

    &#39;
  phenotype_term:
    preferred_term: Acute kidney injury
    term:
      id: HP:0001919
      label: Acute kidney injury
  evidence:
  - reference: PMID:28054946
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Clinical features are attacks of muscle weakness, myalgia, pain and rhabdomyolysis with or without renal failure.
    explanation: Lists renal failure as a complication of rhabdomyolysis in CPT II deficiency.
  - reference: PMID:37933340
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: One of the most common complications is acute kidney injury (AKI) following massive rhabdomyolysis, which is
      managed with aggressive fluid therapy
    explanation: Directly identifies AKI as a common rhabdomyolysis complication in CPT II deficiency.
- name: Hypoketotic hypoglycemia
  frequency: FREQUENT
  description: &#39;Fasting intolerance with low ketone production and hypoglycemia, characteristic of severe infantile and neonatal
    forms due to impaired hepatic fatty acid oxidation.

    &#39;
  phenotype_term:
    preferred_term: Hypoketotic hypoglycemia
    term:
      id: HP:0001985
      label: Hypoketotic hypoglycemia
  evidence:
  - reference: PMID:37933340
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The first two are early-onset severe disorders presenting with marked hypoketotic hypoglycemia, cardiomyopathy,
      and liver dysfunction.
    explanation: Confirms hypoketotic hypoglycemia as a hallmark of severe early-onset CPT II forms.
  context: Severe infantile and neonatal forms
- name: Cardiomyopathy
  frequency: OCCASIONAL
  description: &#39;Cardiac involvement in severe early-onset forms, also reported as a complication in the adult myopathic form.
    One case report documented left ventricular ejection fraction of 40% during acute crisis.

    &#39;
  phenotype_term:
    preferred_term: Cardiomyopathy
    term:
      id: HP:0001638
      label: Cardiomyopathy
  evidence:
  - reference: PMID:37933340
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Echocardiogram showed a left ventricle ejection fraction (LVEF) of 40%.
    explanation: Documents cardiomyopathy with reduced ejection fraction in a myopathic CPT II patient.
  - reference: PMID:37933340
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The first two are early-onset severe disorders presenting with marked hypoketotic hypoglycemia, cardiomyopathy,
      and liver dysfunction.
    explanation: Identifies cardiomyopathy as a feature of severe early-onset CPT II deficiency.
- name: Hepatomegaly
  frequency: OCCASIONAL
  description: &#39;Liver enlargement observed in severe infantile and neonatal forms as part of the hepatocardiomuscular presentation,
    reflecting impaired hepatic fatty acid oxidation and lipid accumulation.

    &#39;
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  evidence:
  - reference: PMID:37933340
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The first two are early-onset severe disorders presenting with marked hypoketotic hypoglycemia, cardiomyopathy,
      and liver dysfunction.
    explanation: Liver dysfunction in early-onset forms is consistent with hepatomegaly.
- name: Elevated creatine kinase
  frequency: VERY_FREQUENT
  description: &#39;Markedly elevated serum creatine kinase during rhabdomyolysis episodes, reflecting skeletal muscle damage.
    CK levels normalize between episodes.

    &#39;
  phenotype_term:
    preferred_term: Elevated circulating creatine kinase concentration
    term:
      id: HP:0003236
      label: Elevated circulating creatine kinase concentration
  evidence:
  - reference: PMID:38650450
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 3 cases presented with clinical manifestations of fever, muscle weakness, and increased muscle enzymes.
    explanation: Documents increased muscle enzymes (including CK) as a clinical manifestation in CPT2-deficient children.
- name: Episodic muscle stiffness
  frequency: FREQUENT
  description: &#39;Muscle stiffness and cramps occurring during or after exercise or illness episodes, often preceding frank
    rhabdomyolysis.

    &#39;
  phenotype_term:
    preferred_term: Exercise-induced muscle stiffness
    term:
      id: HP:0008967
      label: Exercise-induced muscle stiffness
  evidence:
  - reference: PMID:37933340
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The latter is characterized by muscle pain and weakness and stiffness, typically triggered by exercise or febrile
      illnesses
    explanation: Directly describes muscle stiffness as a characteristic feature of myopathic CPT II deficiency.
biochemical:
- name: Long-chain acylcarnitines (C16, C18:1)
  presence: INCREASED
  context: &#39;Elevation of long-chain acylcarnitines, particularly palmitoylcarnitine (C16:0) and oleoylcarnitine (C18:1), is
    the hallmark biochemical signature detectable by tandem mass spectrometry. However, profiles may be normal between crises,
    and sampling during metabolic stress is critical.

    &#39;
  evidence:
  - reference: PMID:38650450
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Five children presented with decreased free carnitine and elevated levels of palmitoyl and octadecenoyl carnitines.
    explanation: Documents elevated C16 and C18:1 acylcarnitines in CPT2-deficient children.
- name: Free carnitine (C0)
  presence: DECREASED
  context: &#39;Free carnitine levels may be decreased or low-normal, reflecting sequestration as long-chain acylcarnitines that
    cannot be metabolized due to CPT-II dysfunction.

    &#39;
  evidence:
  - reference: PMID:38650450
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Five children presented with decreased free carnitine and elevated levels of palmitoyl and octadecenoyl carnitines.
    explanation: Documents decreased free carnitine in CPT2-deficient children alongside elevated acylcarnitines.
- name: Creatine kinase
  presence: INCREASED
  context: &#39;Markedly elevated during rhabdomyolysis episodes, reflecting skeletal muscle damage. Returns to normal between
    episodes. Serves as an acute marker of metabolic crisis severity.

    &#39;
  evidence:
  - reference: PMID:38650450
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 3 cases presented with clinical manifestations of fever, muscle weakness, and increased muscle enzymes.
    explanation: Increased muscle enzymes (CK) documented during symptomatic episodes in CPT2 deficiency.
- name: Palmitoyl-carnitine in muscle
  presence: INCREASED
  context: &#39;Palmitoyl-carnitine (C16:0) accumulates preferentially in oxidative muscle fibers in CPT2 deficiency and directly
    inhibits sarcoplasmic reticulum calcium uptake, linking it to the pathogenesis of muscle contractile dysfunction.

    &#39;
  evidence:
  - reference: PMID:39182841
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Exposing isolated sarcoplasmic reticulum to long-chain acylcarnitines (LCACs) inhibited calcium uptake.
    explanation: Directly supports palmitoyl-carnitine-mediated inhibition of calcium handling in muscle.
genetic:
- name: CPT2 gene variants
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:28054946
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The disease follows an autosomal recessive mode of inheritance.
      explanation: Directly states autosomal recessive inheritance for CPT II deficiency.
  variants:
  - name: CPT2 - p.Ser113Leu (S113L)
    description: &#39;The most common pathogenic variant, found in approximately 90% of myopathic CPT II patients with an allele
      frequency of 60-70%. Produces a thermolabile enzyme with abnormal sensitivity to malonyl-CoA inhibition.

      &#39;
    evidence:
    - reference: PMID:28054946
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: In approximately 90% the molecular basis is a p. S113L mutation in homozygous or heterozygous state with an
        allele frequency of 60%‚Äì70%
      explanation: Quantifies S113L prevalence and allele frequency in myopathic CPT II cohort.
  - name: CPT2 - c.338C&gt;T and c.482G&gt;A compound heterozygote
    description: &#39;Compound heterozygous CPT2 variants identified by whole-genome sequencing in a patient with recurrent rhabdomyolysis
      and normal inter-episode acylcarnitine profiles.

      &#39;
  - name: CPT2 - Various private mutations
    description: &#39;More than 60 mostly private mutations have been described in CPT2 beyond the common S113L variant. Novel
      variants include p.F352L, p.R498L, p.F434S, p.A515P, and c.153-2A&gt;G reported in a Chinese pediatric cohort.

      &#39;
    evidence:
    - reference: PMID:28054946
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: In addition there are more than 60 mostly private mutations
      explanation: Documents the breadth of private CPT2 mutations beyond S113L.
    - reference: PMID:38650450
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: including 3 known variants (p.R631C, p.T589M, and p.D255G) and 5 newly reported variants (p.F352L, p.R498L,
        p.F434S, p.A515P, and c.153-2A&gt;G).
      explanation: Reports novel CPT2 variants identified in a Chinese pediatric cohort.
  features: &#39;CPT II deficiency results from biallelic pathogenic variants in CPT2 encoding the inner mitochondrial membrane
    enzyme CPT-II. Unlike CPT-I, there are no tissue-specific isoforms of CPT-II, so clinical heterogeneity reflects different
    mutations and their impact on enzyme stability and activity. The S113L variant is by far the most common, particularly
    in the myopathic form.

    &#39;
  evidence:
  - reference: PMID:28054946
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#39;Three phenotypes of CPT II deficiency are known: a lethal neonatal form, a severe infantile hepatocardiomuscular
      form, and a mild myopathic form&#39;
    explanation: Describes the three clinical phenotypes of CPT II deficiency.
  - reference: PMID:39429887
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The review detailed 245 cases across various forms, including lethal neonatal, severe infantile hepatocardiomuscular,
      and myopathic forms.
    explanation: Quantifies case distribution across the three clinical subtypes.
environmental:
- name: Prolonged exercise
  description: &#39;Exercise is the most common trigger for rhabdomyolysis episodes, reported in 87% of patients. Sustained muscle
    activity increases reliance on fatty acid oxidation, unmasking the enzymatic defect.

    &#39;
  evidence:
  - reference: PMID:28054946
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most common trigger factors were exercise (87%) and infection (62%).
    explanation: Quantifies exercise as the most common trigger at 87%.
- name: Fasting
  description: &#39;Fasting increases dependency on fatty acid oxidation for energy, precipitating metabolic crises.

    &#39;
  evidence:
  - reference: PMID:28054946
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Trigger factors are prolonged exercise, fasting, fever and exposure to cold
    explanation: Lists fasting as a recognized trigger factor.
- name: Fever and infection
  description: &#39;Fever both increases energy demand and, in thermolabile variants, directly destabilizes the mutant CPT-II
    enzyme. Infections triggered episodes in 62% of patients.

    &#39;
  evidence:
  - reference: PMID:28054946
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most common trigger factors were exercise (87%) and infection (62%).
    explanation: Infection is the second most common trigger at 62%.
  - reference: PMID:28054946
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: the mutated enzyme showed an abnormal thermal destabilization at 40 and 45 ¬∞C
    explanation: Thermolability of S113L variant at fever-range temperatures explains fever as a trigger.
- name: Cold exposure
  description: &#39;Exposure to cold is a recognized trigger for metabolic crises in CPT II deficiency.

    &#39;
  evidence:
  - reference: PMID:28054946
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Trigger factors are prolonged exercise, fasting, fever and exposure to cold
    explanation: Lists cold exposure among recognized trigger factors.
treatments:
- name: Avoidance of metabolic triggers
  description: &#39;Lifestyle modification to avoid prolonged exercise, fasting, cold exposure, and other metabolic stressors
    is the primary preventive strategy. Patients should modify daily activities to prevent recurrent rhabdomyolysis episodes.

    &#39;
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:37933340
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The patient was discharged upon the improvement of renal function with lifestyle modification recommendations.
    explanation: Supports lifestyle modification as a key management strategy.
  - reference: PMID:28054946
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Trigger factors are prolonged exercise, fasting, fever and exposure to cold
    explanation: Identification of trigger factors directly supports avoidance strategy.
- name: High-carbohydrate, low-fat diet
  description: &#39;Dietary modification emphasizing high carbohydrate and low long-chain fat intake to reduce reliance on fatty
    acid oxidation. Medium-chain triglyceride (MCT) supplementation may be used as an alternative energy source since MCT
    can bypass the carnitine shuttle.

    &#39;
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  notes: Dietary fat restriction and MCT supplementation are standard of care for CPT II deficiency but specific clinical
    trial evidence from the available abstracts is limited.
- name: Aggressive fluid resuscitation for rhabdomyolysis
  description: &#39;Emergency management of acute rhabdomyolysis episodes with aggressive intravenous fluid therapy using crystalloid
    solutions to prevent or treat myoglobin-induced acute kidney injury.

    &#39;
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:37933340
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: One of the most common complications is acute kidney injury (AKI) following massive rhabdomyolysis, which is
      managed with aggressive fluid therapy; crystalloid solutions are preferred.
    explanation: Directly recommends aggressive fluid resuscitation with crystalloids for rhabdomyolysis-associated AKI.
  - reference: PMID:37933340
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Fluid resuscitation was started. Acute kidney injury was diagnosed and managed with plasmapheresis and five sessions
      of hemodialysis.
    explanation: Documents clinical management of AKI with fluid resuscitation and renal replacement therapy.
- name: Carnitine supplementation
  description: &#39;L-carnitine supplementation may be used to support conjugation and excretion of accumulated long-chain acyl
    groups, though its use remains debated in fatty acid oxidation disorders. Free carnitine is often decreased in CPT2 deficiency.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:38650450
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Five children presented with decreased free carnitine and elevated levels of palmitoyl and octadecenoyl carnitines.
    explanation: Decreased free carnitine provides rationale for supplementation.
- name: Bezafibrate
  description: &#39;A fibrate drug investigated as a potential pharmacotherapy for CPT II deficiency. A Phase 2 randomized crossover
    trial (NCT00983788) evaluated bezafibrate in adults with CPT II or VLCAD deficiency.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  notes: &#39;Bezafibrate is not yet approved for CPT II deficiency; clinical trial evidence is from Phase 2 studies. The randomized
    trial NCT00983788 was a quadruple-masked crossover design using fatty acid oxidation during moderate exercise as a primary
    outcome. Small open-label studies have reported possible benefit, but efficacy remains uncertain without larger controlled
    outcome data.

    &#39;
  evidence:
  - reference: clinicaltrials:NCT00983788
    supports: SUPPORT
    snippet: The investigators propose to evaluate the effect of bezafibrate on metabolism during exercise in 22 adult patients affected with carnitine palmitoyltransferase II (CPTII) or very-long chain acyl-CoA-dehydrogenase (VLCAD) deficiencies.
    explanation: Directly supports bezafibrate as a studied intervention in adults with CPT II deficiency.
- name: Triheptanoin (UX007)
  description: &#39;An odd-chain triglyceride intended to provide anaplerotic substrate (propionyl-CoA) to support energy metabolism
    in long-chain fatty acid oxidation disorders. Phase 2 clinical trials (NCT01886378, NCT01379625) have evaluated triheptanoin
    in LC-FAOD patients including those with CPT II deficiency.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  notes: &#39;Triheptanoin is not yet specifically approved for CPT II deficiency. Clinical trials in the broader LC-FAOD population
    included CPT II patients. NCT01886378 was a Phase 2 open-label study; NCT01379625 was a Phase 2 randomized double-masked
    comparison with MCT oil.

    &#39;
  evidence:
  - reference: clinicaltrials:NCT01379625
    supports: SUPPORT
    snippet: This study will determine if a new experimental oil called Triheptanoin can decrease the muscle pain and increase the heart function and the amount of energy in patients with long-chain fatty acid oxidation disorders.
    explanation: Supports triheptanoin as a clinical trial intervention for LC-FAOD populations that include CPT II deficiency.
- name: Newborn screening
  description: &#39;CPT II deficiency is detectable by newborn screening via tandem mass spectrometry using elevated long-chain
    acylcarnitines (C16, C18:1) as primary markers. Three of six children in one cohort were diagnosed through neonatal screening.
    However, biochemical abnormalities may only be detectable during metabolic stress.

    &#39;
  treatment_term:
    preferred_term: disease screening
    term:
      id: MAXO:0000124
      label: disease screening
  evidence:
  - reference: PMID:38650450
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Three cases were diagnosed at neonatal screening
    explanation: Documents successful neonatal screening diagnosis in CPT2 deficiency.
  - reference: PMID:38650450
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: An early diagnosis can be facilitated by neonatal blood tandem mass spectrometry screening and genetic testing,
      and most patients have good prognosis after a timely diagnosis and treatment.
    explanation: Supports the value of newborn screening for early diagnosis and improved outcomes.
- name: Genetic counseling
  description: &#39;Counseling for affected families regarding autosomal recessive inheritance, carrier testing, recurrence risk,
    and reproductive options including prenatal genetic testing.

    &#39;
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:28054946
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The disease follows an autosomal recessive mode of inheritance.
    explanation: Autosomal recessive inheritance directly supports the role of genetic counseling for carrier and recurrence
      risk assessment.
clinical_trials:
- name: NCT00983788
  phase: PHASE_II
  status: COMPLETED
  description: Randomized, double-blind, placebo-controlled crossover trial evaluating bezafibrate effects on exercise metabolism in adults with CPT II or VLCAD deficiency.
  target_phenotypes:
  - preferred_term: Exercise intolerance
    term:
      id: HP:0003546
      label: Exercise intolerance
  - preferred_term: Myopathy
    term:
      id: HP:0003198
      label: Myopathy
  evidence:
  - reference: clinicaltrials:NCT00983788
    supports: SUPPORT
    snippet: This study will be an 9-month, randomized, double-blind, placebo-controlled crossover trial.
    explanation: Supports trial design and intervention context for bezafibrate in CPT II/LC-FAOD disease.
- name: NCT01886378
  phase: PHASE_II
  status: COMPLETED
  description: Open-label Phase 2 trial evaluating UX007 (triheptanoin) clinical effects and safety in LC-FAOD.
  target_phenotypes:
  - preferred_term: Myopathy
    term:
      id: HP:0003198
      label: Myopathy
  - preferred_term: Cardiomyopathy
    term:
      id: HP:0001638
      label: Cardiomyopathy
  evidence:
  - reference: clinicaltrials:NCT01886378
    supports: SUPPORT
    snippet: The primary objective of the study was to evaluate the impact of UX007 on acute clinical pathophysiology associated with LC-FAOD following 24 weeks of treatment.
    explanation: Supports UX007/triheptanoin as an evaluated trial intervention in LC-FAOD.
- name: NCT01379625
  phase: PHASE_II
  status: COMPLETED
  description: Phase 2 trial of triheptanoin for long-chain fatty acid oxidation disorders, including outcomes relevant to muscle and cardiac function.
  target_phenotypes:
  - preferred_term: Exercise intolerance
    term:
      id: HP:0003546
      label: Exercise intolerance
  - preferred_term: Cardiomyopathy
    term:
      id: HP:0001638
      label: Cardiomyopathy
  evidence:
  - reference: clinicaltrials:NCT01379625
    supports: SUPPORT
    snippet: This study will determine if a new experimental oil called Triheptanoin can decrease the muscle pain and increase the heart function and the amount of energy in patients with long-chain fatty acid oxidation disorders.
    explanation: Supports triheptanoin trial targeting clinically relevant muscle and cardiac outcomes in LC-FAOD.
notes: &#39;CPT II deficiency is notable for its clinical heterogeneity arising from a single gene (CPT2) without tissue-specific
  isoforms. The most common S113L variant is thermolabile, explaining why the myopathic form presents with crisis-driven symptoms
  during fever or exercise. A key diagnostic pitfall is that acylcarnitine profiles may be completely normal between episodes,
  necessitating sampling during metabolic stress or definitive genetic testing. Recent mechanistic advances (2024) demonstrate
  that muscle damage involves LCAC-mediated sarcoplasmic reticulum calcium uptake inhibition beyond simple energy failure,
  suggesting potential future therapeutic targets.

  &#39;
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Carnitine_Palmitoyltransferase_II_Deficiency.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>